10-Q: Drugs Made in America II Q3: IPO Complete, Search On

Drugs Made in America Acquisition II Corp. reports Q3 2025 results, having completed its $500 million IPO and commenced its search for a pharmaceutical business combination target.

Summary

• Drugs Made in America Acquisition II Corp. (DMIIU) is a blank check company (SPAC) incorporated on August 23, 2024, focused on a business combination in the pharmaceutical industry.
• The company completed its Initial Public Offering (IPO) on September 26, 2025, selling 50,000,000 units at $10.00 per unit, raising $500,000,000.
• Simultaneously, 1,200,000 Private Placement Units were sold to the Sponsor and Cantor Fitzgerald & Co. for $12,000,000.
• A total of $500,000,000 from the IPO and private placement proceeds was placed into a Trust Account, which held $500,109,355 as of September 30, 2025.
• The company reported a net loss of $46,158 for the three months ended September 30, 2025, and a net loss of $143,558 for the nine months ended September 30, 2025.
• Interest earned on cash and investments in the Trust Account amounted to $109,355 for the nine months ended September 30, 2025.
• Management has identified a 'going concern' uncertainty due to the mandatory liquidation date if a business combination is not completed within the 24-month Combination Period.
• Disclosure controls and procedures were deemed not effective as of September 30, 2025, due to inadequate segregation of duties and insufficient written policies and procedures.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the IPO was successful and the trust account is fully funded, the company has not yet identified a business combination target, faces a 'going concern' uncertainty, and has identified material weaknesses in its internal controls. These are typical for a SPAC at this stage, but the control weaknesses add a slight negative.

Positives

• Successfully completed its Initial Public Offering (IPO) on September 26, 2025, raising $500,000,000.
• Secured an additional $12,000,000 through a private placement of units.
• A substantial amount of $500,109,355 is held in the Trust Account, providing capital for a future business combination.
• Generated non-operating income of $109,355 from interest on Trust Account investments for the nine months ended September 30, 2025.

Negatives

• Reported a net loss of $46,158 for the three months ended September 30, 2025, and $143,558 for the nine months ended September 30, 2025.
• Management identified a 'going concern' uncertainty due to the mandatory liquidation date if a business combination is not completed within the Combination Period.
• Disclosure controls and procedures were found to be not effective due to inadequate segregation of duties and insufficient written policies and procedures.

Risks

• Inability to complete a Business Combination successfully within the 24-month Combination Period, leading to liquidation and redemption of public shares.
• Geopolitical instability from the Russia-Ukraine and Israel-Hamas conflicts could lead to market disruptions, volatility, supply chain interruptions, and increased cyber-attacks, adversely affecting the search for a target business.
• Potential for the per share value of assets available for distribution to be less than the Initial Public Offering price ($10.00) in the event of liquidation.
• Reliance on third-party digital technologies and lack of significant investments or resources in data security protection, making the company vulnerable to cybersecurity threats and potential financial loss.
• Inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT, and financial reporting and record keeping, leading to ineffective disclosure controls and procedures.

Future Outlook

The company intends to focus its search for a business combination target within the pharmaceutical industry. It expects to incur significant costs in pursuit of its acquisition plans and does not anticipate generating operating revenues until after the completion of an initial business combination. The company has a 24-month period from the IPO closing (September 26, 2025) to complete a business combination, after which it will liquidate and redeem public shares if unsuccessful.

Management Comments

• Management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
• Management plans to address the 'going concern' uncertainty through a Business Combination, though there is no assurance of success within the Combination Period.
• Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective due to inadequate segregation of duties within account processes due to limited personnel and insufficient written policies and procedures for accounting, IT, and financial reporting and record keeping.

Industry Context

As a Special Purpose Acquisition Company (SPAC), Drugs Made In America Acquisition II Corp. operates within a highly competitive and time-sensitive sector. The company's stated intent to focus on the pharmaceutical industry aligns with a sector known for high R&D costs, regulatory hurdles, and significant M&A activity. The current geopolitical instability and cybersecurity threats mentioned in the filing are broad industry concerns that could impact any potential target business, particularly in a sensitive sector like pharmaceuticals. The company's early stage means it is still in the capital deployment phase, seeking a suitable target, a common characteristic of SPACs post-IPO.

Comparison to Industry Standards

• The company successfully raised $500 million in its IPO and an additional $12 million in a private placement, which is a standard practice for SPACs to secure initial funding and sponsor commitment.
• The placement of $500 million into a trust account, to be invested in U.S. government treasury obligations or money market funds, is a standard protective measure for public shareholders in SPACs, ensuring funds are preserved for a business combination or redemption.
• The 24-month Combination Period is a typical timeframe for SPACs to identify and complete a business combination, aligning with industry norms.
• The disclosure of 'going concern' uncertainty is a standard requirement for SPACs that have not yet completed a business combination, reflecting the inherent time-limited nature of their operations, similar to other blank check companies like Churchill Capital Corp IV or Pershing Square Tontine Holdings prior to their respective business combinations.

Corporate Governance

Related Party Transactions

• The Sponsor forfeited 18,847,722 ordinary shares in February 2025 and an additional 11,500,000 ordinary shares in May 2025 for no consideration.
• The company entered into an Administrative Services Agreement with the Sponsor or an affiliate, agreeing to pay $10,000 per month for office space and administrative support, commencing September 24, 2025. $2,333 was incurred for the three and nine months ended September 30, 2025.
• The CFO, a partner in an advisory firm, provides accounting services to the company, incurring $1,648 and $10,403 in expenses for the three and nine months ended September 30, 2025, respectively.
• The Sponsor issued an unsecured promissory note to the company for up to $325,000 on September 5, 2024, which was repaid on September 29, 2025.
• On September 29, 2025, the company overpaid the Sponsor by $566,269, resulting in a 'Due from Sponsor' balance.
• The Sponsor or an affiliate, or certain officers and directors, may provide 'Working Capital Loans' to finance transaction costs for a Business Combination, with up to $1,500,000 potentially convertible into units.

Stakeholder Impact

• Shareholders: Public shareholders have their investment held in a Trust Account, protected for a business combination or redemption. The value of their rights is contingent on a successful business combination. Founder shares held by the Sponsor are subject to transfer restrictions and forfeiture conditions.
• Underwriters: Entitled to a deferred underwriting fee of $17,500,000 (or up to $21,625,000 if over-allotment is exercised in full) upon completion of a Business Combination.
• Sponsor: Has significant equity interest (Founder Shares and Private Placement Units) and provides administrative services, but also bears liability for certain third-party claims against the Trust Account if a business combination is not completed.

Next Steps

• Identify and complete one or more initial Business Combinations with one or more operating businesses or assets within 24 months from the IPO closing (September 26, 2025).
• Address the identified material weaknesses in disclosure controls and procedures, including inadequate segregation of duties and insufficient written policies.
• Continue to generate non-operating income from interest on the Trust Account investments.

Key Dates

Recommendation

The company is a blank check company (SPAC) that has recently completed its IPO and is in the initial phase of searching for a business combination target in the pharmaceutical industry. Its financial performance reflects this stage, with net losses and a 'going concern' disclosure, which are typical for SPACs. The trust account is fully funded, providing the necessary capital for a future transaction. However, the identified material weaknesses in disclosure controls and the inherent risks of a SPAC (e.g., failure to find a suitable target within the timeframe) warrant caution. There are no immediate catalysts for significant price movement beyond general market sentiment for SPACs. A 'hold' recommendation is appropriate as investors await further developments regarding a potential business combination, which would be the primary driver of future value.

Keywords

SPAC, blank check company, pharmaceutical industry, business combination, IPO, trust account, 10-Q, quarterly report, financial results, corporate governance, risk factors, DMIIU